Royalcare Super Speciality Hospitals
- Unlisted share
- Healthcare
- ISIN INE02C801010
At a glance
Sales
FY26
₹449 Cr
+25.7%on FY25What the company earned from its customers in the year.
Profit
FY26
₹26.11 Cr
+175%on FY25What was left after every cost and tax was paid.
Market valuecalculated
₹3,144 Cr
What the whole company would be worth at GrowFast's indicative price.
Net worth
FY26
₹451 Cr
What the owners would have left on paper if every debt was repaid.
From the company's published figures; sources are beside each figure further down the page.
Key details
- Company
- Royalcare Super Speciality Hospitals
- ISIN
- INE02C801010
- Sector
- Healthcare
- Type of share
- Unlisted equity share
- Indicative price per share
- ₹153.45
- Price last updated
- 12 Oct 2026
- Minimum quantity
- Confirmed by the desk
- How you hold it
- In your own demat account
- Enquiries
- GrowFast desk, on WhatsApp
Indicative prices, illiquid shares. Prices are indicative and can change without notice. Unlisted shares are illiquid: you may not be able to sell when you want to, or at the price shown.
Company
About Royalcare Super Speciality Hospitals
Royalcare Super Speciality Hospital Limited owns and runs a multi-speciality hospital at Neelambur, on the outskirts of Coimbatore, Tamil Nadu. The company was incorporated in 2012 and began treating patients in 2016; the hospital holds NABH and JCI accreditation and a large expansion block was under construction through FY2025-26. It is led by its promoter, the neurosurgeon Dr. K. Madeswaran, as Chairman cum Managing Director, with most of the shares held by directors, their relatives and individual investors.
Written from: royalcarehospital.in
Financials
Ask for the full annual report.
The figures on this page are the headline numbers. The desk can share the latest annual report and anything published since.
Ask for the financials- Sector
- Healthcare
- ISIN
- INE02C801010
- Year of incorporation
- 2012
- Registered office
- Neelambur, Sulur Taluk, Coimbatore, Tamil Nadu
- Promoter
- Dr. K. Madeswaran (named as the 'Identified Promoter' in the AGM notice); promoters hold 13.28% and directors and relatives a further 42.75%
- Key people
- Chairman cum Managing Director: Dr. K. Madeswaran; Director Finance cum CFO: T. Balachander; Company Secretary: K. Rangasamy
- Face value per share
- ₹10
- Equity shares outstanding
- 20,49,08,478 shares
- CIN
- U85100TZ2012PLC018984
- Website
- royalcarehospital.in
Read from: 14th Annual Report 2025-26 (company website), unless another source is shown on a card.
Key data
What the numbers mean
The ratios buyers look at, each said in plain words.
Price to earnings (P/E)calculated
115.4×
At this price you pay ₹115.4 for every ₹1 of profit the company made in the year.
Price to book (P/B)calculated
6.98×
At this price you pay ₹6.98 for every ₹1 of net worth on the company's books.
Profit margincalculated
5.8%
Out of every ₹100 of sales, ₹5.8 was left as profit.
Return on equitycalculated
5.8%
For every ₹100 of the owners' money, the company made ₹5.8 of profit in the year.
Debt to equitycalculated
1.23×
The company has borrowed ₹1.23 for every ₹1 of its owners' money.
- Indicative price
- ₹153.45
- Market valuecalculated
- ₹3,144 Cr
- price × shares
- No. of shares
- 20,49,08,478
- EPS
- ₹1.33
- Book value per share
- ₹21.99
- Face value
- ₹10
Figures marked “calculated” are worked out by GrowFast from its indicative price and the company's published figures for FY2025-26. They move with the price, and they are arithmetic, not a valuation.
Figures in ₹ crore
Financials
Royalcare Super Speciality Hospital Limited. As published in the company's audited reports. GrowFast has not audited them.
Sales, year by year
₹ crore. The darkest bar is the latest year.
FY23 to FY26: ₹305 Cr to ₹449 Cr.
Profit, year by year
₹ crore, after tax. A bar below the line is a loss.
FY23 to FY26: ₹15.68 Cr to ₹26.11 Cr.
| Particulars | FY23 | FY24 | FY25 | FY26Latest |
|---|---|---|---|---|
| Revenue from operations | 305.49 | 332.73 | 356.99 | 448.9▲26% |
| Other income | 5.16 | 5.19 | 4.33 | 5.92▲37% |
| Total income | 310.65 | 337.93 | 361.31 | 454.82▲26% |
| EBITDA (as stated in the Directors' report) | n/a | n/a | 70.08 | 83.13▲19% |
| Depreciation and amortisation | 24.39 | 24.53 | 34.36 | 33.34▼3% |
| Finance costs | 26.84 | 22.15 | 22.24 | 16.17▼27% |
| Profit before tax | 15.56 | 24.32 | 13.48 | 33.61▲149% |
| Profit after tax | 15.68 | 24.48 | 9.48 | 26.11▲175% |
| Earnings per share (basic/diluted) (₹) | 0.95 | 1.43 | 0.53 | 1.33▲151% |
Rupees crore unless marked, standalone (previous GAAP), standalone (Ind AS, restated), standalone (Ind AS). The change shown is the latest year against the year before. Read from: 12th Annual Report 2023-24 (company website), 14th Annual Report 2025-26 (company website).
Ownership
Shareholding pattern
Who owns the company
As of 31 July 2026
42.8%Directors and relatives
- Largest holder
- 42.8%
- Top 3 together
- 91.2%
- Holders named
- 5
- Directors and relatives42.75%
- Indian public35.21%
- Promoters (Indian individuals)13.28%
- Private corporate bodies8.53%
- Others (including NRIs)0.23%
- Total100.00%
Read from: 14th Annual Report 2025-26 (company website) - AGM notice, pre-issue shareholding
Capital history
Fund raise history
| Date and detail | Type | Instrument | Price per share | Amount raised |
|---|---|---|---|---|
| 9 Apr 202611,00,000 equity shares of ₹10 allotted at ₹62 each to five members at the board meeting of 9 April 2026. | Private placement | Equity shares | ₹62 | Not stated |
| 2025-09Members approved a private placement of up to 6 crore shares at the EGM of 13 September 2025; 1,73,50,000 shares were allotted under it and the board has asked members to cancel the unused balance. Price of the earlier tranches was not read from the report. | Private placement | Equity shares | Not stated | Not stated |
Read from: 14th Annual Report 2025-26 (company website)
Leadership
Management
Dr. K. Madeswaran
Chairman cum Managing Director
T. Balachander
Director Finance cum CFO
K. Rangasamy
Company Secretary
Dr. K. Chockalingam
Director
K.P. Alagesan
Director
K.M. Subramanian
Director
K. Muthusamy
Independent Director
P. Appukutty
Independent Director (w.e.f. 14.08.2025)
Read from: 14th Annual Report 2025-26 (company website)
Corporate calendar
Events
- 12 Sept 2026Board outcome on share issueMembers asked to approve up to 4,39,91,522 partly paid shares at ₹62 each (up to ₹272.75 crore) to promoter Dr. K. Madeswaran, and 25,000 DVR shares at ₹74.40Open
- 12 Sept 2026AGM14th AGM called: final dividend of ₹0.20 a share, raising authorised capital to ₹270.03 crore, and enabling shares with differential voting rightsOpen
- 5 Sept 2026DividendRecord date for the FY2025-26 final dividend of ₹0.20 per shareOpen
- 9 Apr 2026Board outcome on share issueBoard allotted 11,00,000 equity shares at ₹62 each on private placementOpen
- 13 Sept 2025EGMEGM approved a private placement of up to 6 crore equity sharesOpen
Reports and filings
Annual reports and results
Each link opens the document where its publisher keeps it.
Before you buy
Six things to check on any unlisted share.
The same list applies to every stock. None of it is advice on this one.
The company's latest financials
Revenue, profit and debt for the last three years, from its audited annual report. Ask the desk for the most recent set.
What the price implies
Compare the price per share with earnings and book value per share, and with listed companies in the same business.
Whether a listing is planned
A company may file for an IPO, delay it or never list. A listing, its timing and its price are never certain.
How you would sell
There is no exchange for these shares. You sell by finding a buyer, which can take time and may be at a lower price.
Lock-in after a listing
Shares bought before an IPO are usually locked in for a period after the company lists. Confirm the current rule before you buy.
Tax on your gains
Unlisted shares are taxed differently from listed ones. Check your position with a tax adviser.
Questions
What buyers ask about this stock.
Not answered here? Ask the desk.
Inquire about Royalcare Super Speciality Hospitals on WhatsAppIs the price shown for Royalcare Super Speciality Hospitals final?
No. It is an indicative price per share. The desk confirms the price and the quantity available when you inquire, and the confirmed price is the one you deal at.
How do I buy these shares?
Press Inquire. It opens a WhatsApp chat with the desk, with this stock already named. After the price and quantity are agreed, a 10% advance locks the deal. Once your KYC is complete you pay the balance, and the shares are transferred to your demat account.
Do I pay anything on this website?
No. No payment is taken and no order is placed on this site. Payment details are shared by the desk only after the deal is agreed.
What do I need before I can buy?
A demat account in your name and the documents for KYC: your identity and demat account details are verified before any deal, as the regulations require.
Can I sell my Royalcare Super Speciality Hospitals shares to GrowFast?
GrowFast buys as well as sells. Press Inquire and tell the desk how many shares you hold; it will come back with what it can offer.
How do I sell Royalcare Super Speciality Hospitals shares I already hold?
Tell the desk how many you hold. If a price is agreed, you transfer the shares from your demat account with a delivery instruction to your depository participant (a DIS, or its online equivalent), and payment follows as agreed with the desk.
Is there a lock-in if the company lists?
Shares held before an IPO are generally locked in for a period after the listing under SEBI's rules, which have changed over time. Ask the desk for the rule that applies today before you buy.
Is buying unlisted shares legal in India?
Yes. Shares of an unlisted company can be bought and sold privately and are transferred between demat accounts. They are not traded on a stock exchange, so the protections of an exchange do not apply.
What is the minimum I can buy?
It differs by stock and by what the desk holds at the time. The desk confirms the minimum quantity when you inquire.
What is an ISIN?
The 12-character code that identifies a security. It is how your depository knows exactly which share is being transferred to your demat account.
Why are unlisted shares riskier than listed ones?
Prices are indicative and can change without notice. Unlisted shares are illiquid: you may not be able to sell when you want to, or at the price shown.
Similar stocks
More in Healthcare
- Anglo-French Drugs & Industries Ltd₹1,585.24 · ₹179 Cr · P/E 7.8
- API Holdings Ltd (PharmEasy)₹6.46 · ₹4,539 Cr
- Dantech Digital Dental Solutions Private Limited₹445.50
- Down Town Hospital Limited₹371.25
- Gynofem Healthcare and Pharmaceutical₹63.36
- Hicks Thermometers India Limited₹1,633.50 · ₹45 Cr · P/E 8.1
Risk disclosure
Prices on this site are indicative, quoted per share, and are not an offer to buy or sell. The price and quantity for any deal are confirmed by GrowFast's desk at the time you deal.
Unlisted, pre-IPO and delisted shares are not traded on a stock exchange. They are illiquid, their prices can move sharply, and you may be unable to sell them when you wish or at all. A company that is expected to list may not do so.
Nothing on this site is investment advice or a promise of returns. Past prices do not predict future prices. Consider your own circumstances, and take independent advice, before you invest.
Inquire opens a WhatsApp chat with GrowFast. No payment is taken and no order is placed on this site.
GrowFast is not affiliated with, sponsored by or endorsed by Royalcare Super Speciality Hospitals. Its name and logo belong to their owner and are shown only to identify the company. Figures about it come from published sources and have not been audited by GrowFast. See the Terms and Conditions.